AlmataBio Acquired by Avalo Therapeutics For 22.5 Million News Events Goodwin - Goodwin Procter
| AVTX Stock | USD 7.25 0.85 10.49% |
Slightly above 60% of Avalo Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Avalo Therapeutics suggests that many traders are alarmed. Avalo Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Avalo Therapeutics' earnings reports, geopolitical events, and overall market trends.
Avalo |
AlmataBio Acquired by Avalo Therapeutics For 22.5 Million News Events Goodwin Goodwin Procter
Read at news.google.com
 |
Avalo Therapeutics Fundamental Analysis
We analyze Avalo Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avalo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avalo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Avalo Therapeutics is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Avalo Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Avalo Therapeutics stock to make a market-neutral strategy. Peer analysis of Avalo Therapeutics could also be used in its relative valuation, which is a method of valuing Avalo Therapeutics by comparing valuation metrics with similar companies.
Peers
Avalo Therapeutics Related Equities
| MOLN | Molecular Partners | 4.70 | ||||
| ACRV | Acrivon Therapeutics, | 2.79 | ||||
| PMVP | Pmv Pharmaceuticals | 1.42 | ||||
| GPCR | Structure Therapeutics | 0.29 | ||||
| EWTX | Edgewise Therapeutics | 0.28 | ||||
| BNTC | Benitec Biopharma | 0.19 | ||||
| ACLX | Arcellx | 0.57 | ||||
| AVTE | Aerovate Therapeutics | 0.82 | ||||
| IPSC | Century Therapeutics | 1.41 | ||||
| ANEB | Anebulo Pharmaceuticals | 1.60 | ||||
| CGEM | Cullinan Oncology | 1.83 | ||||
| ALXO | Alx Oncology | 1.87 | ||||
| VRAX | Virax Biolabs | 2.31 | ||||
| MLYS | Mineralys Therapeutics, | 3.24 | ||||
| BNOX | Bionomics | 3.37 | ||||
| CCCC | C4 Therapeutics | 3.46 | ||||
| ALZN | Alzamend Neuro | 7.29 | ||||
| ANAB | AnaptysBio | 7.48 |
Additional Tools for Avalo Stock Analysis
When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.